A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 490 participants.
Also called NCT02370537
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 490 participants
- Sponsor
- Registry
-
NCT02370537 -
2014-003511-11
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Denmark, Hungary, Latvia, Poland, Slovakia, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT02370537. Randomized; no masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2017-01-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
- Acronym
- PRECISE
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Exocrine Pancreatic Insufficiency
- Intervention (Drug)
- Epanova® (omega-3 carboxylic acids)
- Intervention (Drug)
- Omacor® (omega-3-acid ethyl esters)
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02370537- Content hash
165b54efa6384e20e96bd0ba42e091219a573674927a444c5e47f9b003198a41